Endogenous LXA4 circuits are determinants of pathological angiogenesis in response to chronic injury

American Journal of Pathology

Volumn 176, Issue 1, 2010, Pages 74-84

  Leedom, Alexander J ^a   Sullivan, Aaron B ^a   Dong, Baiyan ^a   Lau, Denise ^a   Gronert, Karsten ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYICOSATETRAENOIC ACID; ARACHIDONATE 15 LIPOXYGENASE; FORMYLPEPTIDE RECEPTOR LIKE 1; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 3; ARACHIDONATE 5 LIPOXYGENASE; AUTACOID; LIPOXIN; LIPOXIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA EPITHELIUM; CORNEA INJURY; CORNEA NEOVASCULARIZATION; ENZYME ACTIVITY; EPITHELIUM CELL; FEMALE; GENE DELETION; MACROPHAGE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUTURE; UPREGULATION; ANIMAL; CORNEA; CORNEA DISEASE; DOWN REGULATION; DRUG EFFECT; ENZYMOLOGY; INFLAMMATION; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHENOTYPE; TOPICAL DRUG ADMINISTRATION; VASCULARIZATION;

ADMINISTRATION, TOPICAL; ANIMALS; ARACHIDONATE 15-LIPOXYGENASE; ARACHIDONATE 5-LIPOXYGENASE; AUTACOIDS; CORNEA; CORNEAL DISEASES; DOWN-REGULATION; GENE DELETION; INFLAMMATION; LIPOXINS; METABOLIC NETWORKS AND PATHWAYS; MICE; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE;

EID: 73949160807     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.090678     Document Type: Article

References (72)

1. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1:27-31
2. Folkman J: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007, 6:273-286
3. Costa C, Incio J, Soares R: Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 2007, 10:149-166
4. Noel A, Jost M, Lambert V, Lecomte J, Rakic JM: Anti-angiogenic therapy of exudative age-related macular degeneration: current progress and emerging concepts. Trends Mol Med 2007, 13:345-352
5. Cao Y, Langer R: A review of Judah Folkman's remarkable achievements in biomedicine. Proc Natl Acad Sci USA 2008;105:13203-13205
6. Gimbrone MA Jr, Cotran RS, Leapman SB, Folkman J: Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst 1974, 52:413-427
7. Streilein JW: Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol 2003, 3:879-889
8. Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, Suthar T, Albuquerque RJ, Richter E, Sakurai E, Newcomb MT, Kleinman ME, Caldwell RB, Lin Q, Ogura Y, Orecchia A, Samuelson DA, Agnew DW, St Leger J, Green WR, Mahasreshti PJ, Curiel DT, Kwan D, Marsh H, Ikeda S, Leiper LJ, Collinson JM, Bogdanovich S, Khurana TS, Shibuya M, Baldwin ME, Ferrara N, Gerber HP, De Falco S, Witta J, Baffi JZ, Raisler BJ, Ambati J: Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006, 443:993-997
9. Chen L, Hamrah P, Cursiefen C, Zhang Q, Pytowski B, Streilein JW, Dana MR: Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. 2004. Ocul Immunol Inflamm 2007, 15:275-278
10. Cursiefen C, Chen L, Saint-Geniez M, Hamrah P, Jin Y, Rashid S, Pytowski B, Persaud K, Wu Y, Streilein JW, Dana R: Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci USA 2006, 103:11405-11410
11. Cursiefen C, Ikeda S, Nishina PM, Smith RS, Ikeda A, Jackson D, Mo JS, Chen L, Dana MR, Pytowski B, Kruse FE, Streilein JW: Spontaneous corneal hem- and lymphangiogenesis in mice with destrin-mutation depend on VEGFR3 signaling. Am J Pathol 2005, 166:1367-1377
12. Tammela T, Zarkada G, Wallgard E, Murtomaki A, Suchting S, Wirzenius M, Waltari M, Hellstrom M, Schomber T, Peltonen R, Freitas C, Duarte A, Isoniemi H, Laakkonen P, Christofori G, Yla-Herttuala S, Shibuya M, Pytowski B, Eichmann A, Betsholtz C, Alitalo K: Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008, 454:656-660
13. Paavonen K, Mandelin J, Partanen T, Jussila L, Li TF, Ristimaki A, Alitalo K, Konttinen YT: Vascular endothelial growth factors C and D and their VEGFR-2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium. J Rheumatol 2002, 29:39-45
14. Kuhn H, O'Donnell VB: Inflammation and immune regulation by 12/ 15-lipoxygenases. Prog Lipid Res 2006, 45:334-356
15. Gronert K: Lipoxins in the eye and their role in wound healing. Prostaglandins Leukot Essent Fatty Acids 2005, 73:221-229
16. Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C, D'Amore PA, Dana MR, Wiegand SJ, Streilein JW: VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004, 113:1040-1050
17. Nie D, Tang K, Diglio C, Honn KV: Eicosanoid regulation of angiogenesis: role of endothelial arachidonate 12-lipoxygenase. Hemost Thromb Vasc Biol 2000, 95:2304-2311
18. Bannenberg GL, Aliberti J, Hong S, Sher A, Serhan C: Exogenous pathogen and plant 15-lipoxygenase initiate endogenous lipoxin a4 biosynthesis. J Exp Med 2004, 199:515-523
19. Brezinski ME, Serhan CN: Selective incorporation of (15S)- hydroxyeicosatetraenoic acid in phosphatidylinositol of human neutrophils: agonist-induced deacylation and transformation of stored hydroxyeicosanoids. Proc Natl Acad Sci USA 1990, 87:6248-6252
20. Levy BD, Romano M, Chapman HA, Reilly JJ, Drazen J, Serhan CN: Human alveolar macrophages have 15-lipoxygenase and generate 15(S)-hydroxy-5,8,11-cis- 13-trans-eicosatetraenoic acid and lipoxins. J Clin Invest 1993, 92:1572-1579
21. Serhan CN, Jain A, Marleau S, Clish C, Kantarci A, Behbehani B, Colgan SP, Stahl GL, Merched A, Petasis NA, Chan L, Van Dyke TE: Reduced inflammation and tissue damage in transgenic rabbits over-expressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J Immunol 2003, 171:6856-6865
22. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN: Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2001, 2:612-619
23. Nassar GM, Morrow JD, Roberts LJ II, Lakkis FG, Badr KF: Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes. J Biol Chem 1994, 269:27631-27634
24. Chavis C, Godard P, Crastes de Paulet A, Damon M: Formation of lipoxins and leukotrienes by human alveolar macrophages incubated with 15(S)-HETE: a model for cellular cooperation between macrophages and airway epithelial cells. Eicosanoids 1992, 5:203-211
25. Cezar-de-Mello PF, Nascimento-Silva V, Villela CG, Fierro IM: Aspirin-triggered Lipoxin A4 inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly. Oncogene 2006, 25:122-129
26. Cezar-de-Mello PF, Vieira AM, Nascimento-Silva V, Villela CG, Barja-Fidalgo C, Fierro IM: ATL-1, an analogue of aspirin-triggered lipoxin A4, is a potent inhibitor of several steps in angiogenesis induced by vascular endothelial growth factor. Br J Pharmacol 2008, 153:956-965
27. Fierro IM, Kutok JL, Serhan CN: Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4). J Pharmacol Exp Ther 2002, 300:385-392
28. Baker N, O'Meara SJ, Scannell M, Maderna P, Godson C: Lipoxin A4: anti-inflammatory and anti-angiogenic impact on endothelial cells. J Immunol 2009, 182:3819-3826
29. Mochizuki N, Kwon YG: 15-lipoxygenase-1 in the vasculature: expanding roles in angiogenesis. Circ Res 2008, 102:143-145
30. Bajpai AK, Blaskova E, Pakala SB, Zhao T, Glasgow WC, Penn JS, Johnson DA, Rao GN: 15(S)-HETE production in human retinal micro-vascular endothelial cells by hypoxia: novel role for MEK1 in 15(S)-HETE induced angiogenesis. Invest Ophthalmol Vis Sci 2007, 48:4930-4938
31. Srivastava K, Kundumani-Sridharan V, Zhang B, Bajpai AK, Rao GN: 15(S)-hydroxyeicosatetraenoic acid-induced angiogenesis requires STAT3-dependent expression of VEGF. Cancer Res 2007, 67:4328 -4336
32. Viita H, Markkanen J, Eriksson E, Nurminen M, Kinnunen K, Babu M, Heikura T, Turpeinen S, Laidinen S, Takalo T, Yla-Herttuala S: 15-lipoxygenase-1 prevents vascular endothelial growth factor A- and placental growth factor-induced angiogenic effects in rabbit skeletal muscles via reduction in growth factor mRNA levels. NO bioactivity, and downregulation of VEGF receptor 2 expression. Circ Res 2008, 102:177-184
33. Funk CD: Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001, 294:1871-1875
34. Funk CD, Chen XS, Johnson EN, Zhao L: Lipoxygenase genes and their targeted disruption. Prostaglandins Other Lipid Mediat 2002, 68-69:303-312
35. Biteman B, Hassan IR, Walker E, Leedom AJ, Dunn M, Seta F, Laniado-Schwartzman M, Gronert K: Interdependence of lipoxin A4 and heme-oxygenase in counter-regulating inflammation during corneal wound healing. FASEB J 2007, 21:2257-2266
36. Gronert K, Maheshwari N, Khan N, Hassan IR, Dunn M, Laniado Schwartzman M: A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense. J Biol Chem 2005, 280:15267-15278
37. Hassan IR, Gronert K: Acute changes in dietary omega-3 and omega-6 polyunsaturated fatty acids have a pronounced impact on survival following ischemic renal injury and formation of renoprotective docosahexaenoic acid-derived protectin D1. J Immunol 2009, 182:3223-3232
38. Seta F, Bellner L, Rezzani R, Regan RF, Dunn MW, Abraham NG, Gronert K, Laniado-Schwartzman M: Heme oxygenase-2 is a critical determinant for execution of an acute inflammatory and reparative response. Am J Pathol 2006, 169:1612-1623
39. Jin Y, Arita M, Zhang Q, Saban DR, Chauhan SK, Chiang N, Serhan CN, Dana R: Novel anti-inflammatory and pro-resolving lipid mediators block inflammatory angiogenesis. Invest Ophthalmol Vis Sci 2009, 50:4743-4752
40. Gronert K, Clish CB, Romano M, Serhan CN: Transcellular regulation of eicosanoid biosynthesis. Methods Mol Biol 1999, 120:119-144
41. Serhan CN, Lu Y, Hong S, Yang R: Mediator lipidomics: search algorithms for eicosanoids, resolvins, and protectins. Methods Enzymol 2007, 432:275-317
42. Murphy RC, Barkley RM, Zemski Berry K, Hankin J, Harrison K, Johnson C, Krank J, McAnoy A, Uhlson C, Zarini S: Electrospray ionization and tandem mass spectrometry of eicosanoids. Anal Biochem 2005, 346:1-42
43. Gonzalez-Periz A, Horrillo R, Ferre N, Gronert K, Dong B, Moran-Salvador E, Titos E, Martinez-Clemente M, Lopez-Parra M, Arroyo V, Claria J: Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J 2009, 23:1946-1957
44. 4 ELISA. J Pharmacol Exp Ther 1998, 287:779-790
45. Clish CB, Levy BD, Chiang N, Tai HH, Serhan CN: Oxidoreductases in lipoxin A4 metabolic inactivation: a novel role for 15-onoprostaglandin 13-reductase/leukotriene B4 12-hydroxydehydrogenase in inflammation. J Biol Chem 2000, 275:25372-25380
46. Bellner L, Vitto M, Patil KA, Dunn MW, Regan R, Laniado-Schwartzman M: Exacerbated corneal inflammation and neovascularization in the HO-2 null mice is ameliorated by biliverdin. Exp Eye Res 2008, 87:268-278
47. Chiang N, Serhan CN, Dahlen SE, Drazen JM, Hay DW, Rovati GE, Shimizu T, Yokomizo T, Brink C: The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev 2006, 58:463-487
48. Nie D, Honn KV: Eicosanoid regulation of angiogenesis in tumors. Semin Thromb Hemost 2004, 30:119-125
49. Serhan CN, Chiang N, Van Dyke TE: Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008, 8:349-361
50. Aliberti J, Hieny S, Reis e Sousa C, Serhan CN, Sher A: Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity. Nat Immunol 2002, 3:76-82
51. Aliberti J, Serhan C, Sher A: Parasite-induced lipoxin A4 is an endogenous regulator of IL-12 production and immunopathology in Toxoplasma gondii infection. J Exp Med 2002, 196:1253-1262
52. Liminga M, Oliw EH: Studies of lipoxygenases in the epithelium of cultured bovine cornea using an air interface model. Exp Eye Res 2000, 71:57-67
53. Gronert K: Lipid autacoids in inflammation and injury responses: a matter of privilege. Mol Interv 2008, 8:28-35
54. Devchand PR, Arita M, Hong S, Bannenberg G, Moussignac RL, Gronert K, Serhan CN: Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense. FASEB J 2003, 17:652-659
55. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LA, Perretti M, Rossi AG, Wallace JL: Resolution of inflammation: state of the art, definitions and terms. FASEB J 2007, 21:325-332
56. Schwab JM, Chiang N, Arita M, Serhan CN: Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007, 447: 869-874
57. Gilroy DW, Lawrence T, Perretti M, Rossi AG: Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov 2004, 3:401-416
58. Calandria JM, Marcheselli VL, Mukherjee PK, Uddin J, Winkler JW, Petasis NA, Bazan NG: Selective survival rescue in 15-lipoxygenase-1 deficient retinal pigment epithelial cells by the novel docosahexaenoic acid-derived mediator, neuroprotectin D1. J Biol Chem 2009, 284: 17877-17882
59. Serhan CN, Yang R, Martinod K, Kasuga K, Pillai PS, Porter TF, Oh SF, Spite M: Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 2009, 206:15-23
60. Qin Q, Patil KA, Gronert K, Sharma SC: Neuroprotectin D1 inhibits retinal ganglion cell death following axotomy. Prostaglandins Leukot Essent Fatty Acids 2008, 79:201-207
61. Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, Serhan CN, Bazan NG: A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 2005, 115:2774-2783
62. Connor KM, SanGiovanni JP, Lofqvist C, Aderman CM, Chen J, Higuchi A, Hong S, Pravda EA, Majchrzak S, Carper D, Hellstrom A, Kang JX, Chew EY, Salem N Jr, Serhan CN, Smith LE: Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 2007, 13:868-873
63. Chang MS, Schneider C, Roberts RL, Shappell SB, Haselton FR, Boeglin WE, Brash AR: Detection and subcellular localization of two 15S-lipoxygenases in human cornea. Invest Ophthalmol Vis Sci 2005, 46:849-856
64. Liminga M, Fagerholm P, Oliw EH: Lipoxygenases in corneal epithelia of man and cynomolgus monkey. Exp Eye Res 1994, 59:313-321 65. Munger KA, Montero A, Fukunaga M, Uda S, Yura T, Imai E, Kaneda Y, Valdivielso JM, Badr KF: Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis. Proc Natl Acad Sci USA 1999, 96:13375-13380
65. Shen J, Herderick E, Cornhill JF, Zsigmond E, Kim HS, Kuhn H, Guevara NV, Chan L: Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. J Clin Invest 1996, 98:2201-2208
66. Godson C, Brady HR: Lipoxins: novel anti-inflammatory therapeutics? Curr Op Invest Drugs 2000, 1:380-385
67. McMahon B, Mitchell S, Brady HR, Godson C: Lipoxins: revelations on resolution. Trends Pharmacol Sci 2001, 22:391-395
68. Gronert K, Gewirtz A, Madara JL, Serhan CN: Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release. J Exp Med 1998, 187:1285-1294
69. Huang LC, Petkova TD, Reins RY, Proske RJ, McDermott AM: Multi-functional roles of human cathelicidin (LL-37) at the ocular surface. Invest Ophthalmol Vis Sci 2006, 47:2369-2380
70. Sholley MM, Gimbrone MA Jr, Cotran RS: The effects of leukocyte depletion on corneal neovascularization. Lab Invest 1978, 38:32-40
71. Abraham NG, Kappas A: Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 2008, 60:79-127
72. Cross MJ, Claesson-Welsh L: FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001, 22:201-220